Aptamer Group Plc · LSE:APTA
Aptamer — FY2022 Earnings Presentation
24 slides from Aptamer's earnings presentation, June 2022
Slide 1: FY22 Full Year Results Presentation
FY22 Full Year Results Presentation • Dr Arron Tolley • Jenny Cutler Chief Executive Officer & Founder Interim Chief Financial Officer [email protected] [email protected] • Dr David Bunka Chief Technical Officer & Founder [email protected] Science unlimited
Slide 2: Disclaimer
DISCLAIMER Private and Confidential - for personal use only and not for distribution This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking s
Slide 3: Presentation team
Presentation team Dr Arron Tolley Jenny Cutler CEO Interim CFO • Co-founded Aptamer Group in 2008 • Over 20 years of finance leadership • Globally-recognised technical & experience, including AIM and main commercial leader in aptamers listed companies • Delivered several patent-pending • Chartered A
Slide 4: Business snapshot
Business snapshot • Solve intractable problems for biotech and big pharma by Service level agreements and licence deals with developing Optimer® binders, which are a disruptive technology with key large stakeholders across life sciences advantages over antibodies and other alternatives • Disrupting
Slide 5: Introduction to Aptamer Group
Introduction to Aptamer Group Science unlimited
Slide 6: Enabling the life science industry with the Optimer platform
Enabling the life science industry with the Optimer® platform • We discover and develop custom affinity binders using our proprietary Optimer ® platform to generate tools to enable new approaches in therapeutics, diagnostics and research applications What we do • We strive to deliver transformationa
Slide 7: Leveraging the Optimer platform via multiple strategies
Leveraging the Optimer® platform via multiple strategies • Expertise Optimer® platform • IP: patents & know-how • HTP automation Arising IP & technical/scientific Development Partnering programme knowledge transfer of Proprietary products Multiple revenue streams In-house Out-licence development • U
Slide 8: Aptamer Group business units
Aptamer Group business units • Contract research services • Enabling Diagnostics • Enabling Therapeutics • Global research antibody market valued • Global diagnostic speciality antibodies • Global antibody therapeutic market at $3.6bn in 2020 market valued at $19.9bn in 2020 worth in excess of $114.
Slide 9: Operational review
Operational review Science unlimited
Slide 10: A clear strategy to grow
A clear strategy to grow Underpinned by £10.8m IPO fundraise, Aptamer Group is accelerating growth and increasing value capacity over multiple verticals to deliver more solutions and higher value engagements Scale-up & Automation Platform innovation Commercial expansion and service development £ Wor
Slide 11: Key highlights for FY22
Key highlights for FY22 Aptamer Group • Raised gross proceeds of £10.8 million in conjunction with AIM listing on 22 December 2021 Aptamer Solutions • Contract secured with a top five global pharma company to develop Optimer® binders as QC reagents for a novel neurodegenerative disease vaccine (Jul)
Slide 12: Post-year end highlights
Post-year end highlights Aptamer Group • In October 2022, the planned relocation to larger purpose-built laboratories was completed. This will allow Aptamer to scale its automation and operational efficiency and service the increasing demand for Optimer® binders Aptamer Solutions • Multiple contract
Slide 13: Progress: Scale up – business relocation
Progress: Scale up – business relocation • Scaling of current Optimer® development platform to service expected demand • Scale-up includes expanding automation systems and increasing capacity of the current platform • Additional equipment has been purchased and is being integrated into the platform
Slide 14: Progress: Commercial expansion
Progress: Commercial expansion • Appointment of Jenny Cutler as Interim Chief Financial Officer • Appointment of Alastair Fleming as Chief Operating Officer • Headcount and expertise increasing, with 44% increase to 49 employees during FY22, increased to 54 since year end • Increased sales and marke
Slide 15: Progress: Platform innovation
Progress: Platform innovation • Building exemplification data of Optimer® binders to support application across the life sciences • Optimer® + • Work to integrate our novel nucleotide chemistry platform is underway • Will broaden applications and improve the performance of existing Optimer® technolo
Slide 16: Optimer+ a 3rd generation affinity ligand
Optimer ® + a 3rd generation affinity ligand 1st Gen 2nd Gen 3rd Gen Antibodies Protein Optimer® Optimer® + Optimer® + Challenges that new affinity scaffolds ligands seek to address advantages • Only ~15% human proteins studied with current affinity ligands • New targets enable new • Large opportuni
Slide 17: Financial review
Financial review Science unlimited
Slide 18: Income statement
Income statement • Group revenue of £4.0m (YoY increase of 152%) • Gross profit margin improvement • Adjusted EBITDA* loss of £1.7m, reduced from £2.4m in 2021 • Headcount at 30 June 2022 of 49 (34 at 30 June 2021) Year ended 30 Jun 22 15 mths ended 30 Jun 21 £’000 £’000 Revenue 4,036 1,600 Group re
Slide 19: Balance sheet
Balance sheet • Cash of £6.7m reflecting the funds raised on placing; £9.6m net proceeds • Additional right of use asset arising from the signing of the new lease at York Science Park • Corresponding liability is included in interest bearing loans and borrowings • Other increases in inventories and
Slide 20: Cash flow
Cash flow • Net cash outflow from operations of £2.4m (2021: £1.4m) • £0.4m investment in tangible and intangible assets (2021: £0.4m) • £9.6m net proceeds from the placing • £0.5m lease payments (2021: £0.2m) Year ended 30 Jun 22 15 mths ended 30 Jun 21 £’000 £’000 Cash (£m) Cash used in operations
Slide 21: Summary & outlook
Summary & outlook Science unlimited
Slide 22: Outlook
Outlook • Continuing to deliver strong revenue growth with new contracts signed, repeat business across all business units with large global players • Revenue in line with expectations for FY23 • We expect accelerated growth to come from dedicated commercial focus building traction in Europe, USA, a
Slide 23: Summary
Summary Service level agreements and licence deals with • Increased revenue in FY22 by 152% to £4.0m in line with large stakeholders across life sciences expectations • Relocated to larger premises to scale automation and built state of the art laboratories gaining operational efficiencies to servic
Slide 24: Thank you
Thank you W: aptamergroup.com E: [email protected] T: +44 (0) 1904 217404